Cargando…

A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments

Cost-effectiveness analysis provides information on the potential value of new cancer treatments, which is particularly pertinent for decision makers as demand for treatment grows while healthcare budgets remain fixed. A range of decision-analytic modelling approaches can be used to estimate cost ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Bullement, Ash, Cranmer, Holly L., Shields, Gemma E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885507/
https://www.ncbi.nlm.nih.gov/pubmed/31485867
http://dx.doi.org/10.1007/s40258-019-00513-3
_version_ 1783474746812268544
author Bullement, Ash
Cranmer, Holly L.
Shields, Gemma E.
author_facet Bullement, Ash
Cranmer, Holly L.
Shields, Gemma E.
author_sort Bullement, Ash
collection PubMed
description Cost-effectiveness analysis provides information on the potential value of new cancer treatments, which is particularly pertinent for decision makers as demand for treatment grows while healthcare budgets remain fixed. A range of decision-analytic modelling approaches can be used to estimate cost effectiveness. This study summarises the key modelling approaches considered in oncology, alongside their advantages and limitations. A review was conducted to identify single technology appraisals (STAs) submitted to the National Institute for Health and Care Excellence (NICE) and published papers reporting full economic evaluations of cancer treatments published within the last 5 years. The review was supplemented with the existing methods literature discussing cancer modelling. In total, 100 NICE STAs and 124 published studies were included. Partitioned-survival analysis (n = 54) and discrete-time state transition structures (n = 41) were the main structures submitted to NICE. Conversely, the published studies reported greater use of discrete-time state transition models (n = 102). Limited justification of model structure was provided by authors, despite an awareness in the existing literature that the model structure should be considered thoroughly and can greatly influence cost-effectiveness results. Justification for the choice of model structure was limited and studies would be improved with a thorough rationale for this choice. The strengths and weaknesses of each approach should be considered by future researchers. Alternative methods (such as multi-state modelling) are likely to be utilised more frequently in the future, and so justification of these more advanced methods is paramount to their acceptability to inform healthcare decision making. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40258-019-00513-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6885507
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-68855072019-12-12 A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments Bullement, Ash Cranmer, Holly L. Shields, Gemma E. Appl Health Econ Health Policy Review Article Cost-effectiveness analysis provides information on the potential value of new cancer treatments, which is particularly pertinent for decision makers as demand for treatment grows while healthcare budgets remain fixed. A range of decision-analytic modelling approaches can be used to estimate cost effectiveness. This study summarises the key modelling approaches considered in oncology, alongside their advantages and limitations. A review was conducted to identify single technology appraisals (STAs) submitted to the National Institute for Health and Care Excellence (NICE) and published papers reporting full economic evaluations of cancer treatments published within the last 5 years. The review was supplemented with the existing methods literature discussing cancer modelling. In total, 100 NICE STAs and 124 published studies were included. Partitioned-survival analysis (n = 54) and discrete-time state transition structures (n = 41) were the main structures submitted to NICE. Conversely, the published studies reported greater use of discrete-time state transition models (n = 102). Limited justification of model structure was provided by authors, despite an awareness in the existing literature that the model structure should be considered thoroughly and can greatly influence cost-effectiveness results. Justification for the choice of model structure was limited and studies would be improved with a thorough rationale for this choice. The strengths and weaknesses of each approach should be considered by future researchers. Alternative methods (such as multi-state modelling) are likely to be utilised more frequently in the future, and so justification of these more advanced methods is paramount to their acceptability to inform healthcare decision making. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40258-019-00513-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2019-09-04 2019 /pmc/articles/PMC6885507/ /pubmed/31485867 http://dx.doi.org/10.1007/s40258-019-00513-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Bullement, Ash
Cranmer, Holly L.
Shields, Gemma E.
A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
title A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
title_full A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
title_fullStr A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
title_full_unstemmed A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
title_short A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
title_sort review of recent decision-analytic models used to evaluate the economic value of cancer treatments
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885507/
https://www.ncbi.nlm.nih.gov/pubmed/31485867
http://dx.doi.org/10.1007/s40258-019-00513-3
work_keys_str_mv AT bullementash areviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments
AT cranmerhollyl areviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments
AT shieldsgemmae areviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments
AT bullementash reviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments
AT cranmerhollyl reviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments
AT shieldsgemmae reviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments